Truist Adjusts Price Target on CRISPR Therapeutics to $100 From $120, Maintains Buy Rating
Truist Adjusts Price Target on CRISPR Therapeutics to $100 From $120, Maintains Buy Rating
Truist将crispr therapeutics的目标价从$120调整至$100，维持买入评级。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
资讯热榜
更新时间